Preclinical toxicity of a new oral anticancer drug, CI-994 (Acetyldinaline), in rats and dogs
- 1 January 1997
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 15 (4) , 295-310
- https://doi.org/10.1023/a:1005937502511
Abstract
CI-994 (acetyldinaline) is an orally active anticancer drug currently in Phase 1 clinical trials. To assess int preclinical toxicity, CI-994 was administered orally as suspensions to Wistar rats...Keywords
This publication has 18 references indexed in Scilit:
- Preclinical antitumor activity of CI-994Investigational New Drugs, 1996
- Subchronic Intravenous Toxicity of the Antineoplastic Drug, Amsacrine, in Male Wistar RatsFundamental and Applied Toxicology, 1996
- Role of a small molecular weight phosphoprotein in the mechanism of action of CI‐994 (N‐acetyldinaline)International Journal of Cancer, 1995
- Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogsAnti-Cancer Drugs, 1994
- Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.1993
- Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia.1993
- Three-month effects of MDL 19,660 on the canine platelet and erythrocyteFundamental and Applied Toxicology, 1992
- Haemoprotection against cytostatic drugs by stem cell inhibitionTrends in Pharmacological Sciences, 1991
- REGULATION OF MEGAKARYOCYTE PLOIDY INVIVO IN THE RAT1990
- SYNTHESIS, TOXICITY, AND THERAPEUTIC EFFICACY OF 4-AMINO-N-(2'-AMINOPHENYL)-BENZAMIDE - A NEW COMPOUND PREFERENTIALLY ACTIVE IN SLOWLY GROWING TUMORS1985